信立泰：获得药品注册证书

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for the registration certificate of Ennadustat tablets, which are indicated for the treatment of anemia in chronic kidney disease (CKD) patients undergoing dialysis [1] Company Summary - Xinlitai announced the approval of Ennadustat tablets on the evening of September 5 [1] - The drug is specifically approved for use in patients with chronic kidney disease who are undergoing both hemodialysis and peritoneal dialysis [1]